- Home
- HNVR vs IZTC Comparison
HNVR vs IZTC Comparison
Compare HNVR & IZTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- IZTC
- Stock Information
- Founded
- HNVR 2008
- IZTC 2019
- Country
- HNVR United States
- IZTC United States
- Employees
- HNVR N/A
- IZTC N/A
- Industry
- HNVR Commercial Banks
- IZTC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HNVR Finance
- IZTC Health Care
- Exchange
- HNVR Nasdaq
- IZTC Nasdaq
- Market Cap
- HNVR 129.7M
- IZTC 111.5M
- IPO Year
- HNVR 2022
- IZTC 2024
- Fundamental
- Price
- HNVR $24.64
- IZTC $11.30
- Analyst Decision
- HNVR Buy
- IZTC
- Analyst Count
- HNVR 1
- IZTC 0
- Target Price
- HNVR $22.00
- IZTC N/A
- AVG Volume (30 Days)
- HNVR 15.0K
- IZTC 52.0K
- Earning Date
- HNVR 01-27-2025
- IZTC 02-15-2025
- Dividend Yield
- HNVR 1.64%
- IZTC N/A
- EPS Growth
- HNVR N/A
- IZTC N/A
- EPS
- HNVR 1.85
- IZTC N/A
- Revenue
- HNVR $64,015,000.00
- IZTC N/A
- Revenue This Year
- HNVR N/A
- IZTC N/A
- Revenue Next Year
- HNVR $15.94
- IZTC N/A
- P/E Ratio
- HNVR $13.23
- IZTC N/A
- Revenue Growth
- HNVR 6.86
- IZTC 145.01
- 52 Week Low
- HNVR $13.62
- IZTC $8.50
- 52 Week High
- HNVR $27.14
- IZTC $23.00
- Technical
- Relative Strength Index (RSI)
- HNVR 62.26
- IZTC N/A
- Support Level
- HNVR $21.01
- IZTC N/A
- Resistance Level
- HNVR $23.67
- IZTC N/A
- Average True Range (ATR)
- HNVR 0.99
- IZTC 0.00
- MACD
- HNVR 0.23
- IZTC 0.00
- Stochastic Oscillator
- HNVR 97.84
- IZTC 0.00
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About IZTC Invizyne Technologies Inc. Common Stock
Invizyne Technologies Inc is redefining biomanufacturing by leveraging cell-free multi-step enzyme-based systems to efficiently transform natural or renewable resources into highly sought-after chemicals. It believes that its biomanufacturing platform, known as SimplePath, will be a significant alternative to the current methods of chemical compound production, which are generally chemical synthesis, natural extraction, and synthetic biology. its objective with SimplePath is to enable the efficient production of a diverse range of chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform consists of a series of modular cascading enzyme-based biomanufacturing systems that leverage natural processes to perform complex chemical conversions.